Sudarshan Pharma Industries Ltd. Approved for Production Linked Incentive (PLI) Scheme Revision

Sudarshan Pharma Industries Ltd. has received approval for a revision in the Production Linked Incentive (PLI) Scheme for the promotion of domestic manufacturing of critical Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs) in India. The approval is for the production of Vitamin B6 and Vitamin B1, with a revised scheduled commercial operation date of 31.3.2025. The company has also been granted approval to change the location of the greenfield projects from MIDC, Maharashtra to GIDC, Gujarat, and to revise the scheduled commercial operation date for the bulk drugs, Vitamin B1 (chemical synthesis route) and Vitamin B6, to be commissioned by 31.12.2027.